Wed, Nov 26, 2014, 5:12 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Astex Pharmaceuticals, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • thefletch82 thefletch82 Sep 20, 2006 5:39 PM Flag

    ARCH conference

    There is no reason to bash the selling dacogen in EU. For heaven's sake the FDA approved the freaking thing...I would be utterly shocked if the EU doesn't approve it. What I want to hear about is the sale of Nipent in the EU. Come on baby get it sold for 18M! That would be awesome in my opinion.

    I think I have this right but maybe someone can explain to me if I'm wrong, isn't the 51M in cash before the North America sale of Nipent? That means SUPG actually has 85M in cash right? Someone tell me if I'm wrong.

    Thanks
    Fletch

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • No they received only 14M on closing of the nipent U.S. sale and 5M from Cilag . They will receive another 20M for Nipent upon certain milestones. Supg probably will record around 61m-65M in cash at the end of 3rd quarter. They had received 2nd quarter about 20M milestone Dacogen approval and spent 9M for Montigen and 2.2M for early termination of Nipent rights.

 
ASTX
8.4950.0000(0.00%)Oct 10 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.